Food and Drug Administration - December 7, 2005
Richard Klein & Kimberly Struble

This week marks the tenth anniversary of the approval of the first protease inhibitor. In December of 1995, a then new class of drug for the treatment of HIV/AIDS in combination with other antiretroviral drugs represented an historic landmark in the treatment of HIV/AIDS. Protease inhibitors helped establish a new treatment standard of triple combination therapy, significantly improving the lives and health of people living with HIV in the United States and around the world.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

051207
FD051203

SOURCE: Food and Drug Administration (FDA).

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .